209 related articles for article (PubMed ID: 29963728)
1. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
3. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
Urick ME; Yu EJ; Bell DW
Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
[TBL] [Abstract][Full Text] [Related]
4. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
[TBL] [Abstract][Full Text] [Related]
5. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
8. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
9. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
[TBL] [Abstract][Full Text] [Related]
10. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
Koo J; Wu X; Mao Z; Khuri FR; Sun SY
J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
[TBL] [Abstract][Full Text] [Related]
11. Recent insight into the role of FBXW7 as a tumor suppressor.
Yumimoto K; Nakayama KI
Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
[TBL] [Abstract][Full Text] [Related]
12. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
[TBL] [Abstract][Full Text] [Related]
13. SCF(FBXW7)-mediated degradation of p53 promotes cell recovery after UV-induced DNA damage.
Galindo-Moreno M; Giráldez S; Limón-Mortés MC; Belmonte-Fernández A; Reed SI; Sáez C; Japón MÁ; Tortolero M; Romero F
FASEB J; 2019 Oct; 33(10):11420-11430. PubMed ID: 31337255
[TBL] [Abstract][Full Text] [Related]
14. Alteration of tumor suppressors changes the endometrial tumor spectrum.
Mayo LD
EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
[TBL] [Abstract][Full Text] [Related]
15. FBXW7: a critical tumor suppressor of human cancers.
Yeh CH; Bellon M; Nicot C
Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
[TBL] [Abstract][Full Text] [Related]
16.
Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
[No Abstract] [Full Text] [Related]
17. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
18. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract][Full Text] [Related]
19. STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.
Liu L; Jiang H; Wang X; Wang X; Zou L
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239181
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of FBXW7 loss of function in human cancers.
Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]